A Promising Opportunity
Investing in host-targeted therapy presents a promising opportunity in the healthcare sector. As the understanding of host-pathogen interactions deepens, there's growing recognition of the potential benefits of therapies that focus on modulating host factors.
Compelling reasons to consider
investing in host-targeted therapy
- Innovative Approach
- Broad Spectrum Treatment
- Reduced Side Effects
- Growing Market
- Long-term Value
Investing in host-targeted therapy for infections can be a strategic investment choice, offering both financial potential and the opportunity to contribute to significant advancements in healthcare.
Our innovation presents a compelling business opportunity positioned at the convergence of two lucrative markets:
The sepsis therapeutic sector, valued at $3.5 billion in 2021 and projected to attain a value of USD 6.2 Billion by 2028
The sepsis diagnostic market, valued at $596 million in 2021 and is projected to grow from $840.5 million in 2023 to $1,603.3 million by 2030.
Numbers That Matter
1 million
The estimated number of deaths worldwide each year due to antibiotic-resistant infections.
10 million
The projected number of deaths due to antibiotic-resistant infections by 2050 if no action is taken to curb resistance.
50%
The percentage of antibiotics prescribed in outpatient settings that are unnecessary or inappropriate, contributing to the development of resistance.
<1%
The percentage of new antibiotics approved by the FDA between 1980 and 2018 that address the most urgent antibiotic-resistant pathogens.
Numbers That Matter
1 million
The estimated number of deaths worldwide each year due to antibiotic-resistant infections.
10 million
The projected number of deaths due to antibiotic-resistant infections by 2050 if no action is taken to curb resistance.
50%
The percentage of antibiotics prescribed in outpatient settings that are unnecessary or inappropriate, contributing to the development of resistance.
<1%
The percentage of new antibiotics approved by the FDA between 1980 and 2018 that address the most urgent antibiotic-resistant pathogens.
Our approach is to prevent the bacteria
from attaching to the inside of the blood vessels in the
first place. In doing so the bacteria
cannot make the blood vessel become leaky and
therefore they cannot escape the bloodstream
The ultimate goal is the organs don’t become damaged and therefore increases the possibility of the patient surviving.
This is a new approach to treating sepsis which acts on the blood vessels of septic patients rather than on the bacteria – so it’s a non-antibiotic treatment.This means that it wont have any effect of anti-bacterial resistance.